Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
189.60
-4.62 (-2.38%)
At close: Oct 31, 2025, 4:00 PM EDT
187.00
-2.60 (-1.37%)
After-hours: Oct 31, 2025, 7:59 PM EDT
Insmed Revenue
Insmed had revenue of $142.34M in the quarter ending September 30, 2025, with 52.36% growth. This brings the company's revenue in the last twelve months to $447.02M, up 30.34% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$447.02M
Revenue Growth
+30.34%
P/S Ratio
80.73
Revenue / Employee
$351,709
Employees
1,271
Market Cap
40.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
INSM News
- 1 day ago - Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 4 days ago - Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 8 days ago - Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List - PRNewsWire
- 14 days ago - CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - PRNewsWire
- 15 days ago - Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 - PRNewsWire
- 16 days ago - Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 - PRNewsWire
- 4 weeks ago - Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality - Seeking Alpha